Dorota Religa, MD, PhD, Karolinska Institutet, Solna, Sweden, talks about why anti-amyloid therapies, such as lecanemab, will be of limited use for most patients with Alzheimer’s disease (AD), a debate that took place at CONy 2024. While some patients may benefit, most don’t meet the strict eligibility criteria due to factors such as comorbidities and age. For instance, patients on anticoagulants or with conditions like diabetes may not qualify. Trials also excluded those over 90 years old and those with frailty. Prof. Religa stresses the need to balance the early treatment focus with care for advanced patients. She advocates for a more inclusive approach to benefit a broader range of patients with AD. This interview took place at the 18th Annual Congress on Controversies in Neurology (CONy 2024) in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
